medigraphic.com
Academia Mexicana de Neurología, A.C.

2014, Number 3

Rev Mex Neuroci 2014; 15 (3)

Usefulness of trihexyphenidyl in the prevention of movement disorders induced by typical neuroleptics

Scherle-Matamoros CE, Terroba-Chambi CJ, Marot-Casañas M

Language: Spanish
References: 18
Page: 147-151
PDF size: 124.35 Kb.


ABSTRACT

Introduction: Drugs with anticholinergic effects have been considered for many years as first-line medications for treatment and prevention of movement disorders induced by neuroleptics. However, its usefulness is not well established.
Objetive: To describe the experience with trihexyphenidyl therapy for the prevention of dyskinesias in patients with chronic psychosis medicated with classical antipsychotic drugs.
Methods: A quasi-experimental, observational study was performed on patients with chronic psychosis medicated with fluphenazine decanoate and other neuroleptics, under treatment or not with trihexyphenidyl.
Results: A total of 64 patients were included, among whom schizophrenia predominated; 56.2% (36 cases) was medicated with trihexyphenidyl from the start of treatment with fluphenazine decanoate. The mean treatment period was 66.9 months. In 60.9% (39 patients) some variant of movement disorders were found and these were more frequent in cases medicated with trihexyphenidyl (61.5 vs. 38.5%). The predominant movement disorders were parkinsonism (n = 19, 29.7%), followed by akathisia (n = 7, 10.9%) and tardive dyskinesia (n = 4, 11.1%).
Conclusion: In this observational study it was not evidenced the usefulness of trihexyphenidyl in the prophylaxis of neurolepticinduced dyskinesias.


REFERENCES

  1. 1 . Jesiæ MP, Jesiæ A, Filipoviæ JB, Zivanoviæ O. Extrapyramidal syndromes caused by antipsychotics. Med Pregl 2012; 65: 521-6.

  2. Rashkis HA, Smarr ER. Protection against reserpine-induce parkinsonism. Am J Psychiatry 1957; 113: 1116.

  3. Desmarais JE, Beauclair L, Margolese HC. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? J Psychopharmacol 2012; 26: 1167-74.

  4. Cancelli I, Beltrame M, Gigli GL, Valiente Ml. Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients. NeurolSci 2009; 30: 87-92.

  5. Straker M. Clinical factors in tardive-dyskinesia. Psychiatr J UnivOtt 1980; 5: 28-33.

  6. Lang AE, Fahn S. Assesment of Parkinson’s disease. Quantification of neurological deficit. T Munsat Stoneham, Butterworths; 1989, p. 285-309.

  7. Ayd FJ Jr. A survey of drug-induced extrapyramidal reactions. J Am Med Assoc 1961; 175: 1054-560.

  8. Bressan RA, Jones HM, Pilowsky LS. Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity. J Psychopharmacol 2004;18: 124-7.

  9. Claxton KL, Chen JJ, Swope DM. Drug-Induced Movement Disorders. Journal of Pharmacy Practice 2007; 20: 415-29.

  10. Janno S, Holi M, Tuisku K, Wahlbeck K. Prevalence of neurolepticinduced movement disorders in chronic schizophreniainpatients. Am J Psychiatry 2004; 161: 160-3.

  11. Susatia F, Fernandez HH. Drug-Induced Parkinsonism. Current Treatment Options in Neurology 2009; 11: 162-9.

  12. Halliday J, Farrington S, Macdonald S, Mac Ewan T, Sharkey V, McCreadie R. Nithsdale Schizophrenia Surveys 23: movement disorders: 20-year review. Br J Psychiatry 2002; 181: 422-7.

  13. Cancelli I, Beltrame M, Gigli GL, Valente M. Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients. NeurolSci 2009; 30: 87-92.

  14. Wirshing WC. Movement disorders associated with neuroleptictreatment. J Clin Psychiatry 2001; 62: 15-18.

  15. Saifee TA, Edwards MJ. Tardive movement disorders: a practical approach. Practical Neurology 2011; 11: 341-8.

  16. Soares KVS, McGrath JJ. Medicamentos anticolinérgicos para la discinesia tardía inducida por neurolépticos (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue 3. Chichester, UK: John Wiley & Sons, Ltd).

  17. Rosenheck RA. Open forum: effectiveness versus efficacy of second generation antipsychotics: haloperidol without anticholinergics as a comparator. Psychiatr Serv 2005; 56: 85-92.

  18. Keepers GA, Casey DE: Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry 1991; 148: 85-9.




2020     |     www.medigraphic.com